Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors

Kazuhiko Nakagawa, Hironobu Minami, Masayuki Kanezaki, Akihira Mukaiyama, Yoshiyuki Minamide, Hisao Uejima, Takayasu Kurata, Toshiji Nogami, Kenji Kawada, Hirofumi Mukai, Yasutsuna Sasaki, Masahiro Fukuoka